BioNumerik

www.bionumerik.com
Profile Unclaimed

BioNumerik Reviews

0 Reviews
N/A
0 Reviews

Recommend to a friend
Approve of CEO
(no image)
Frederick H. Hausheer
0 Ratings

BioNumerik Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Website www.bionumerik.com
Headquarters San Antonio, TX
Size 50 to 149 Employees
Founded Unknown
Type Company - Private
Industry Biotech & Pharmaceuticals
Revenue $5 to $10 million (USD) per year

BioNumerik Pharmaceuticals does biopharmaceutical drug development by the numbers. Using a multi-discipline process of identifying potential cancer drugs, the company has brought two candidates into late-stage development. Lead candidate Tavocept, which has FDA fast-track status, may prevent nerve and kidney damage caused by cancer therapies. BioNumerik's Karenitecin candidate is an advanced formulation of an existing cancer drug and is being evaluated for treatment of solid tumors. The firm relies heavily on computer models and simulations to identify promising drug... More

Work at BioNumerik? Share Your Experiences

BioNumerik

 
Click to Rate
or